Skip to main content
ENDO 2026 Main banner

Neuroendocrinology and Pituitary

MON-038 - Long-Term CAM2029 Octreotide Depot Maintains Biochemical and Symptom Control in Acromegaly Across A 4-Week Dosing Interval and during Intervals >28 Days: Data from the ACROINNOVA 2 Trial

Monday, June 15, 2026
9:00 AM - 2:00 PM CT
Location: ENDOExpo; Poster Floor
Background
Patients with acromegaly may experience waning biochemical and symptom control toward the end of dosing intervals with previously approved standard-of-care injectable somatostatin receptor ligands (SRLs). CAM2029 is a novel, long-acting octreotide subcutaneous depot for self-administration. In ACROINNOVA 1 (NCT04076462), CAM2029 demonstrated stable biochemical and symptom control across 4-week (W) dosing intervals in patients previously controlled on SRLs. We report descriptive data for insulin-like growth factor I (IGF-I) and symptom control over the final dosing interval of long-term CAM2029 in ACROINNOVA 2 (NCT04125836).

Methods
Patients were either directly enrolled (DE; IGF-I ≤2×upper limit of normal [ULN]) or continued from ACROINNOVA 1 (prior-CAM2029; prior-placebo [PBO]; IGF-I ≤ULN). CAM2029 20 mg was administered every 4W (±1W) for 52W (prior-PBO, W24–52). The final dose was received at W48 and the end of core phase (EOCP) assessment scheduled for W52. IGF-I levels were assessed throughout, including at W48 (pre dose), W50 and W52/EOCP; Acromegaly Index of Severity (AIS) was assessed throughout, including at W48 and W52/EOCP. Some W52/EOCP assessments were delayed; patients were grouped by on-time (≤28 days post-W48 dose) and later (>28 days post-W48 dose) assessment.

Results
Of 135 patients enrolled, 122 received the final dose at W48, had IGF-I assessment at W52/EOCP and are included in this analysis. The proportion of patients with IGF-I ≤ULN was stable across the dosing interval: 48.8% at W48, 55.7% at W50 and 55.7% at W52/EOCP. Mean AIS Overall Scores (standard deviation [SD]) were stable across W48 (3.2 [3.0]) to W52/EOCP (3.4 [3.1]) in the overall group.
Eighty-six patients had on-time W52/EOCP assessments (prior-CAM2029 n=22, prior-PBO n=13, DE n=51). Mean interval from W48 dose to W52/EOCP assessment was 25.0 days. IGF-I ≤ULN was achieved by 47.7% at W48, 57.3% at W50 and 60.5% at W52/EOCP. At these timepoints, IGF-I control rates were 77.3%, 90.5% and 95.5% for prior-CAM2029, 84.6%, 91.7% and 92.3% for prior-PBO and 25.5%, 34.7%, 37.3% for DE groups. Overall, patients with on-time W52/EOCP assessments had stable mean AIS Overall Scores (SD) from W48 (3.1 [3.0]) to W52/EOCP (3.2 [3.1]).
Thirty-six patients had later W52/EOCP assessments (prior-CAM2029 n=11, prior-PBO n=4, DE n=21). Mean interval from W48 dose to W52/EOCP assessment was 33.2 days. IGF-I ≤ULN was achieved by 50.0% at W48, 51.5% at W50 and 44.4% at W52/EOCP. At these timepoints, IGF-I control rates were 90.9%, 90.0% and 81.8% for prior-CAM2029, 75.0%, 100% and 75.0% for prior-PBO and 23.8%, 21.1% and 19.0% for DE. CAM2029 maintained stable mean AIS Overall Scores (SD) in patients with later assessments (W48, 3.6 [3.0]; W52/EOCP, 3.7 [3.1]).

Conclusion
Long-term CAM2029 maintains stable disease control over a 4W dosing interval and can reduce the waning control seen with other injectable SRLs.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*